tbuckley/cabot-search huggingface dataset:
Plant-Based Diet and Survival Among Patients with Metastatic Colorectal Cancer
Authors: En Cheng, Fang-Shu Ou, Clare Gatten, Chao Ma, Alan P Venook, Heinz-Josef Lenz, Eileen M O’Reilly, Peter T Campbell, Chaoyuan Kuang, Bette J Caan, Charles D Blanke, Kimmie Ng, Jeffrey A Meyerhardt
Journal: JNCI Journal of the National Cancer Institute (2024)

Abstract Background A plant-based diet is associated with better survival among patients with nonmetastatic colorectal cancer (CRC), but its association in metastatic CRC is unknown. Methods Using an National Cancer Institute–sponsored trial (CALGB/SWOG 80405), we included 1284 patients who completed validated food frequency questionnaires at the initiation of metastatic CRC treatment. We calculated 3 indices: overall plant-based diet index (PDI), which emphasized consumption of all plant foods while reducing animal food intake; healthful plant-based diet index (hPDI), which emphasized consumption of healthful plant foods such as whole grains, fruits, and vegetables; and unhealthful plant-based diet index (uPDI), which emphasized consumption of less healthful plant foods such as fruit juices, refined grains, and sugar-sweetened beverages. We estimated the associations of 3 indices (quintiles) with overall survival (OS) and progression-free survival (PFS) using multivariable Cox proportional hazards regression. Results We observed 1100 deaths and 1204 progression events (median follow-up = 6.1 years). Compared with the lowest quintile, patients in the highest quintile of PDI had significantly better survival (hazard ratio [HR] for OS = 0.76 [0.62-0.94], Ptrend = .004; PFS = 0.81 [0.66-0.99], Ptrend = .09). Similar findings were observed for hPDI (HR for OS = 0.81 [0.65-1.01], Ptrend = .053; PFS = 0.80 [0.65-0.98], Ptrend = .04), whereas uPDI was not associated with worse survival (HR for OS = 1.16 [0.94-1.43], Ptrend = .21; PFS = 1.12 [0.92-1.36], Ptrend = .42). Conclusions Our study suggests that a plant-based diet, especially when rich in healthful plant foods, is associated with better survival among patients with metastatic CRC. The cause of survival benefits warrants further investigation.
Assessment of Intermediate-Term Mortality Following Pancreatectomy for Cancer
Authors: Lauren M Janczewski, Michael R Visenio, Rachel Hae-Soo Joung, Anthony D Yang, David D Odell, Elizabeth C Danielson, Mitchell C Posner, Ted A Skolarus, David J Bentrem, Karl Y Bilimoria, Ryan P Merkow
Journal: JNCI Journal of the National Cancer Institute (2024)

Abstract Background Pancreatic cancer remains highly lethal, and resection represents the only chance for cure. Although patients are counseled regarding short-term (0-3 months) mortality, little is known about mortality 3-6 months (intermediate-term) following surgery. We assessed predictors of intermediate-term mortality, evaluated hospital-level variation, and developed a nomogram to predict intermediate-term mortality risk. Methods Patients undergoing pancreatic cancer resection were identified from the National Cancer Database (2010-2020). Multivariable logistic regression identified predictors of intermediate-term mortality and assessed differences between short-term and intermediate-term mortality. Multinomial regression grouped by intermediate-term mortality quartiles evaluated hospital-level variation. A neural network model was constructed to predict intermediate-term mortality risk. All statistical tests were 2-sided. Results Of 45 297 patients, 3974 (8.9%) died within 6 months of surgery of which 2216 (5.1%) were intermediate-term. Intermediate-term mortality was associated with increasing T category, positive nodes, lack of systemic therapy, and positive margins (all P &amp;lt; .05) compared with survival beyond 6 months. Compared with short-term mortality, intermediate-term mortality was associated with treatment at high-volume hospitals, positive nodes, neoadjuvant systemic therapy, adjuvant radiotherapy, and positive margins (all P &amp;lt; .05). Median intermediate-term mortality rate per hospital was 4.5% (interquartile range [IQR] = 2.6-6.5). Highest quartile hospitals had decreased odds of treatment with neoadjuvant systemic therapy, neoadjuvant radiotherapy, and adjuvant radiotherapy (all P &amp;lt; .05). The neural network nomogram was highly accurate (accuracy = 0.9499; area under the receiver operating characteristics curve = 0.7531) in predicting individualized intermediate-term mortality risk. Conclusion Nearly 10% of patients undergoing pancreatectomy for cancer died within 6 months, of which one-half occurred in the intermediate term. These data have real-world implications to improve shared decision making when discussing curative-intent pancreatectomy.
NEJM at ESC — Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease
Authors: Eric J. Rubin, Jane Leopold, Stephen Morrissey
Journal: New England Journal of Medicine (2024)

Audio Interview NEJM at ESC — Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease 4m 8s Download
Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease
Authors: Min Soo Cho, Do-Yoon Kang, Jung-Min Ahn, Sung-Cheol Yun, Yong-Seog Oh, Chang Hoon Lee, Eue-Keun Choi, Ji Hyun Lee, Chang Hee Kwon, Gyung-Min Park, Hyung Oh Choi, Kyoung-Ha Park, Kyoung-Min Park, Jongmin Hwang, Ki-Dong Yoo, Young-Rak Cho, Ji Hyun Kim, Ki Won Hwang, Eun-Sun Jin, Osung Kwon, Ki-Hun Kim, Seung-Jung Park, Duk-Woo Park, Gi-Byoung Nam
Journal: New England Journal of Medicine (2024)

BackgroundDespite consistent recommendations from clinical guidelines, data from randomized trials on a long-term antithrombotic treatment strategy for patients with atrial fibrillation and stable coronary artery disease are still lacking.MethodsWe conducted a multicenter, open-label, adjudicator-masked, randomized trial comparing edoxaban monotherapy with dual antithrombotic therapy (edoxaban plus a single antiplatelet agent) in patients with atrial fibrillation and stable coronary artery disease (defined as coronary artery disease previously treated with revascularization or managed medically). The risk of stroke was assessed on the basis of the CHA2DS2-VASc score (scores range from 0 to 9, with higher scores indicating a greater risk of stroke). The primary outcome was a composite of death from any cause, myocardial infarction, stroke, systemic embolism, unplanned urgent revascularization, and major bleeding or clinically relevant nonmajor bleeding at 12 months. Secondary outcomes included a composite of major ischemic events and the safety outcome of major bleeding or clinically relevant nonmajor bleeding.ResultsWe assigned 524 patients to the edoxaban monotherapy group and 516 patients to the dual antithrombotic therapy group at 18 sites in South Korea. The mean age of the patients was 72.1 years, 22.9% were women, and the mean CHA2DS2-VASc score was 4.3. At 12 months, a primary-outcome event had occurred in 34 patients (Kaplan–Meier estimate, 6.8%) assigned to edoxaban monotherapy and in 79 patients (16.2%) assigned to dual antithrombotic therapy (hazard ratio, 0.44; 95% confidence interval [CI], 0.30 to 0.65; P<0.001). The cumulative incidence of major ischemic events at 12 months appeared to be similar in the trial groups. Major bleeding or clinically relevant nonmajor bleeding occurred in 23 patients (Kaplan–Meier estimate, 4.7%) in the edoxaban monotherapy group and in 70 patients (14.2%) in the dual antithrombotic therapy group (hazard ratio, 0.34; 95% CI, 0.22 to 0.53).ConclusionsIn patients with atrial fibrillation and stable coronary artery disease, edoxaban monotherapy led to a lower risk of a composite of death from any cause, myocardial infarction, stroke, systemic embolism, unplanned urgent revascularization, or major bleeding or clinically relevant nonmajor bleeding at 12 months than dual antithrombotic therapy. (Funded by the CardioVascular Research Foundation and others; EPIC-CAD ClinicalTrials.gov number, NCT03718559.)
Why Have We Not Been Able to Demonstrate Reduced Mortality in Patients With HFmrEF/HFpEF?
Authors: Toru Kondo, Alasdair D. Henderson, Kieran F. Docherty, Pardeep S. Jhund, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray
Journal: Journal of the American College of Cardiology (2024)
Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis
Authors: Pardeep S Jhund, Atefeh Talebi, Alasdair D Henderson, Brian L Claggett, Muthiah Vaduganathan, Akshay S Desai, Carolyn S P Lam, Bertram Pitt, Michele Senni, Sanjiv J Shah, Adriaan A Voors, Faiez Zannad, Scott D Solomon, John J V McMurray
Journal: The Lancet (2024)

SummaryBackgroundMineralocorticoid receptor antagonists (MRAs) reduce hospitalisations and death in patients with heart failure and reduced ejection fraction (HFrEF), but the benefit in patients with heart failure and mildly reduced ejection fraction (HFmrEF) or heart failure and preserved ejection fraction (HFpEF) is unclear. We evaluated the effect of MRAs in four trials that enrolled patients with heart failure across the range of ejection fraction.MethodsThis is a prespecified, individual patient level meta-analysis of the RALES (spironolactone) and EMPHASIS-HF (eplerenone) trials, which enrolled patients with HFrEF, and of the TOPCAT (spironolactone) and FINEARTS-HF (finerenone) trials, which enrolled patients with HFmrEF or HFpEF. The primary outcome of this meta-analysis was a composite of time to first hospitalisation for heart failure or cardiovascular death. We also estimated the effect of MRAs on components of this composite, total (first or repeat) heart failure hospitalisations (with and without cardiovascular deaths), and all-cause death. Safety outcomes were also assessed, including serum creatinine, estimated glomerular filtration rate, serum potassium, and systolic blood pressure. An interaction between trials and treatment was tested to examine the heterogeneity of effect in these populations. This study is registered with PROSPERO, CRD42024541487.Findings13 846 patients were included in the four trials. MRAs reduced the risk of cardiovascular death or heart failure hospitalisation (hazard ratio 0·77 [95% CI 0·72–0·83]). There was a statistically significant interaction by trials and treatment (p for interaction=0·0012) due to the greater efficacy in HFrEF (0·66 [0·59–0·73]) compared with HFmrEF or HFpEF (0·87 [0·79–0·95]). We observed significant reductions in heart failure hospitalisation in the HFrEF trials (0·63 [0·55–0·72]) and the HFmrEF or HFpEF trials (0·82 [0·74–0·91]). The same pattern was observed for total heart failure hospitalisations with or without cardiovascular death. Cardiovascular death was reduced in the HFrEF trials (0·72 [0·63–0·82]) but not in the HFmrEF or HFpEF trials (0·92 [0·80–1·05]). All-cause death was also reduced in the HFrEF trials (0·73 [0·65–0·83]) but not in the HFmrEF or HFpEF trials (0·94 [0·85–1·03]). With an MRA, the risk of hyperkalaemia was doubled compared with placebo (odds ratio 2·27 [95% CI 2·02–2·56]), but the incidence of serious hyperkalaemia (serum potassium >6·0 mmol/L) was low (2·9% vs 1·4%); the risk of hypokalaemia (potassium <3·5 mmol/L) was halved (0·51 [0·45–0·57]; 7% vs 14%).InterpretationSteroidal MRAs reduce the risk of cardiovascular death or heart failure hospitalisation in patients with HFrEF and non-steroidal MRAs reduce this risk in patients with HFmrEF or HFpEF.FundingNone.
NEJM at ESC — Finerenone in Heart Failure for Mildly Reduced or Preserved Ejection Fraction
Authors: Eric J. Rubin, Jane Leopold, Stephen Morrissey
Journal: New England Journal of Medicine (2024)

Audio Interview NEJM at ESC — Finerenone in Heart Failure for Mildly Reduced or Preserved Ejection Fraction 3m 28s Download
Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART pooled analysis of cardiovascular, kidney, and mortality outcomes
Authors: Muthiah Vaduganathan, Gerasimos Filippatos, Brian L. Claggett, Akshay S. Desai, Pardeep S. Jhund, Alasdair Henderson, Meike Brinker, Peter Kolkhof, Patrick Schloemer, James Lay-Flurrie, Prabhakar Viswanathan, Carolyn S. P. Lam, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Peter Rossing, Luis M. Ruilope, Stefan D. Anker, Bertram Pitt, Rajiv Agarwal, John J. V. McMurray, Scott D. Solomon
Journal: Nature Medicine (2024)
CTA-Derived Pericoronary Fat Attenuation Index Predicts Allograft Rejection and Cardiovascular Events in Heart Transplant Recipients
Authors: Angelo Sansonetti, Marta Belmonte, Marco Masetti, Luca Bergamaschi, Pasquale Paolisso, Laura Borgese, Francesco Angeli, Matteo Armillotta, Riet Dierckx, Sofie Verstreken, Nicola Gaibazzi, Domenico Tuttolomondo, Chiara Baldovini, Emanuele Barbato, Paola Rucci, Joseph Bartunek, Luciano Potena, Marc Vanderheyden, Carmine Pizzi
Journal: JACC. Cardiovascular imaging (2024)
Zibotentan in Microvascular Angina: A Randomized, Placebo-Controlled, Crossover Trial
Authors: Andrew Morrow, Robin Young, George R. Abraham, Stephen Hoole, John P. Greenwood, Jayanth Ranjit Arnold, Mohamed El Shibly, Mayooran Shanmuganathan, Vanessa Ferreira, Roby Rakhit, Gavin Galasko, Aish Sinha, Divaka Perera, Rasha Al-Lamee, Ioakim Spyridopoulos, Ashish Kotecha, Gerald Clesham, Thomas J. Ford, Anthony Davenport, Sandosh Padmanabhan, Lisa Jolly, Peter Kellman, Juan Carlos Kaski, Robin A. Weir, Naveed Sattar, Julie Kennedy, Peter W. Macfarlane, Paul Welsh, Alex McConnachie, Colin Berry
Journal: Circulation (2024)

Background: Microvascular angina is associated with dysregulation of the endothelin system and impairments in myocardial blood flow, exercise capacity, and health-related quality of life. The G allele of the noncoding single nucleotide polymorphism RS9349379 enhances expression of the endothelin-1 gene ( EDN1 ) in human vascular cells, potentially increasing circulating concentrations of Endothelin-1 (ET-1). Whether zibotentan, an oral ET-A receptor selective antagonist, is efficacious and safe for the treatment of microvascular angina is unknown. Methods: Patients with microvascular angina were enrolled in this double-blind, placebo-controlled, sequential crossover trial of zibotentan (10 mg daily for 12 weeks). The trial population was enriched to ensure a G allele frequency of 50% for the RS9349379 single nucleotide polymorphism. Participants and investigators were blinded to genotype. The primary outcome was treadmill exercise duration (seconds) using the Bruce protocol. The primary analysis estimated the mean within-participant difference in exercise duration after treatment with zibotentan versus placebo. Results: A total of 118 participants (mean ±SD; years of age 63.5 [9.2 ]; 71 [60.2% ] females; 25 [21.2% ] with diabetes) were randomized. Among 103 participants with complete data, the mean exercise duration with zibotentan treatment compared with placebo was not different (between-treatment difference, −4.26 seconds [95 ] CI, −19.60 to 11.06] P =0.5871). Secondary outcomes showed no improvement with zibotentan. Zibotentan reduced blood pressure and increased plasma concentrations of ET-1. Adverse events were more common with zibotentan (60.2%) compared with placebo (14.4%; P &lt;0.001). Conclusions: Among patients with microvascular angina, short-term treatment with a relatively high dose (10 mg daily) of zibotentan was not beneficial. Target-related adverse effects were common.
Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination Compared With Placebo for Initial Treatment of Hypertension
Authors: Anthony Rodgers, Abdul Salam, Aletta E Schutte, William C Cushman, H Asita de Silva, Gian Luca Di Tanna, Diederick Grobbee, Krzysztof Narkiewicz, Dike B Ojji, Neil R Poulter, Markus P Schlaich, Suzanne Oparil, Wilko Spiering, Bryan Williams, Jackson T Wright, Alexis Gutierez, Aliu Sanni, Poopalan Lakshman, Deirdre McMullen, Gotabhaya Ranasinghe, Chris Gianacas, Mathangi Shanthakumar, Xiaoqiu Liu, Nelson Wang, Paul Whelton
Journal: Journal of the American College of Cardiology (2024)
Glymphotherapeutics for Alzheimer’s disease: Time to move the needle
Authors: ArunSundar MohanaSundaram, Mohammad Mofatteh, Ghulam Md Ashraf, Domenico Praticò
Journal: Ageing Research Reviews (2024)

Alzheimer's disease (AD), the most predominant neurodegenerative disease and a quintessential entity within the dementia umbrella, is a global public health crisis. While the lack of disease modifying therapies has been a weak point in AD treatment, the success of recently approved monoclonal antibody-based therapeutics (aducanumab and lecanemab) targeted at the removal of amyloid-beta (Aβ) peptides in the brain is still under debate. There are multiple safety concerns about these approved neurotherapeutics including amyloid-related imaging abnormalities, stroke, meningitis, encephalitis, and even death. Novel paradigms focused on aquaporin-4-mediated neuro-perivascular Aβ and Tau protein clearance pathway are garnering attention. In this paper, we argue that orchestrating the drug discovery focused on glymphatic clearance-facilitating drugs ("glymphotherapeutics") might be a potentially novel and viable strategy to mitigate the progression and improve the clinical outcomes of AD.
Multimodal Deep Learning Improves Recurrence Risk Prediction in Pediatric Low-Grade Gliomas
Authors: Maryamalsadat Mahootiha, Divyanshu Tak, Zezhong Ye, Anna Zapaishchykova, Jirapat Likitlersuang, Juan Carlos Climent Pardo, Aidan Boyd, Sridhar Vajapeyam, Rishi Chopra, Sanjay P Prabhu, Kevin X Liu, Hesham Elhalawani, Ali Nabavizadeh, Ariana Familiar, Sabine Mueller, Hugo J W L Aerts, Pratiti Bandopadhayay, Keith L Ligon, Daphne Haas-Kogan, Tina Y Poussaint, Hemin Ali Qadir, Ilangko Balasingham, Benjamin H Kann
Journal: Neuro-Oncology (2024)

Abstract Background Postoperative recurrence risk for pediatric low-grade gliomas (pLGGs) is challenging to predict by conventional clinical, radiographic, and genomic factors. We investigated if deep learning (DL) of magnetic resonance imaging (MRI) tumor features could improve postoperative pLGG risk stratification. Methods We used a pretrained DL tool designed for pLGG segmentation to extract pLGG imaging features from preoperative T2-weighted MRI from patients who underwent surgery (DL-MRI features). Patients were pooled from 2 institutions: Dana Farber/Boston Children’s Hospital (DF/BCH) and the Children’s Brain Tumor Network (CBTN). We trained 3 DL logistic hazard models to predict postoperative event-free survival (EFS) probabilities with (1) clinical features, (2) DL-MRI features, and (3) multimodal (clinical and DL-MRI features). We evaluated the models with a time-dependent Concordance Index (Ctd) and risk group stratification with Kaplan–Meier plots and log-rank tests. We developed an automated pipeline integrating pLGG segmentation and EFS prediction with the best model. Results Of the 396 patients analyzed (median follow-up: 85 months, range: 1.5–329 months), 214 (54%) underwent gross total resection and 110 (28%) recurred. The multimodal model improved EFS prediction compared to the DL-MRI and clinical models (Ctd: 0.85 (95% CI: 0.81–0.93), 0.79 (95% CI: 0.70–0.88), and 0.72 (95% CI: 0.57–0.77), respectively). The multimodal model improved risk-group stratification (3-year EFS for predicted high-risk: 31% versus low-risk: 92%, P &amp;lt; .0001). Conclusions DL extracts imaging features that can inform postoperative recurrence prediction for pLGG. Multimodal DL improves postoperative risk stratification for pLGG and may guide postoperative decision-making. Larger, multicenter training data may be needed to improve model generalizability.
50532 VISIBLE: Guselkumab Demonstrated Significant Scalp Psoriasis Clearance and Scalp Itch Improvements at Week 16 in Skin of Color Participants With Moderate-to-Severe Plaque Psoriasis
Authors: Amy McMichael, Linda Stein Gold, Jennifer Soung, Chesahna Kindred, Olivia Choi, Daphne Chan, Jenny Jeyarajah, Candrice R. Heath, Tina Bhutani, Maxwell Sauder, Andrew Alexis
Journal: Journal of the American Academy of Dermatology (2024)
54025 A Maximum-Use Trial of Ruxolitinib Cream in Children ≥2 to &lt;12 Years Old with Atopic Dermatitis (AD): Patient-Reported Outcomes (PROs) at Week 8
Authors: Seth B. Forman, Andrea L. Zaenglein, Julie S. Shepard, Howard Kallender, Brett Angel, Yutzu Kuo, Robert Bissonnette
Journal: Journal of the American Academy of Dermatology (2024)
53928 Tapinarof Cream 1% Once Daily: Interim Analysis of ADORING 3 Phase 3 Long-term Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis
Authors: Robert Bissonnette, Linda Stein Gold, Leon Kircik, Lawrence F. Eichenfield, H. Chih-Ho Hong, Kim A. Papp, Anna M. Tallman, Stephen C. Piscitelli, David S. Rubenstein, Philip M. Brown, Jonathan I. Silverberg
Journal: Journal of the American Academy of Dermatology (2024)
53899 Treatment success with sarecycline for treatment of acne vulgaris (AV): Comparison of results from randomized controlled trials (RCTs) and the real-world (RW) PROSES study
Authors: Emmy Graber, James Del Rosso, Ismail Kasujee, Raidah Salem, Paul Tomondy, Hilary Baldwin
Journal: Journal of the American Academy of Dermatology (2024)
53788 The patient-reported impact of flares on quality of life in pediatric and adolescent patients with moderate-to-severe atopic dermatitis: a real-world study in the United States and Europe
Authors: Lawrence Eichenfield, Vivian Shi, JiaDe Yu, Evangeline Pierce, Amber Reck Atwater, Jenny Austin, Phoebe Salmon, James Piercy, Peter Anderson, Amy Paller
Journal: Journal of the American Academy of Dermatology (2024)
50200 Short-chain fatty acid ameliorates imiquimod-induced skin and systemic inflammation and alters gut microbiota in mice: a metagenome association analysis
Authors: Yi-Ju Chen, Hsiu J. Ho, Ching-Hung Tseng, Yu-Fen Chen, Sin-Ting Wang, Jeng-Jer Shieh, Chun-Ying Wu
Journal: Journal of the American Academy of Dermatology (2024)
50659 A Cooling Gel Cream with Oat Provides Improvement in Quality of Life for Everyday Lifestyle Impact, and Itch Frequency &amp; Bother, in Atopic Dermatitis Patients
Authors: Zoe Diana Draelos, Brenda Edison, Adegboyega Adenaike, Neena Tierney, Katie Spisak, Judith A. Nebus
Journal: Journal of the American Academy of Dermatology (2024)
49450 3-Dimensional tissue clearing and quantification of epidermal innervation in pruritic atopic dermatitis skin
Authors: Dai Hyun Kim, Hyun Mo Lee, Yoon Jae Kim, Jun Hyuk Cho, Soo Hong Seo, Hyo Hyun Ahn, Woong Sun, Byung-Jo Kim, Im Joo Rhyu
Journal: Journal of the American Academy of Dermatology (2024)
53959 Treatment With Upadacitinib Increases the Achievement of Minimal Disease Activity Among Patients With Moderate-to-Severe Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1 and Measure Up 2)
Authors: Jonathan I. Silverberg, Melinda J. Gooderham, Norito Katoh, Valeria Aoki, Andrew E. Pink, Yousef Binamer, Wan-Ju Lee, Brian M. Calimlim, Amy Gamelli, Andreas Wollenberg
Journal: Journal of the American Academy of Dermatology (2024)
54206 A Hispanic dermatology-rheumatology clinic: enhancing healthcare care beyond connective tissue diseases.
Authors: Mayra Alejandra Reyes Soto, Sonia Chavez-Alvarez, Alejandra Brown-Herrera, Minerva Gomez-Flores, Jorge Ocampo-Candiani, Ivan Hernandez-Galarza, Dionicio Angel Galarza-Delgado
Journal: Journal of the American Academy of Dermatology (2024)
52843 A dermocosmetic reduces the peak number of non-inflammatory lesions and the peak sebum level during the menstrual cycle
Authors: Edileia Bagatin, Marion Mesrobian, Anna Veriato, Estelle Gilbert, Beatriz Sant'Anna, Claire Deloche, Stéphanie Leclerc-Mercier, Christos Zouboulis, Staedtisches Klinikum Dessau
Journal: Journal of the American Academy of Dermatology (2024)
53429 Use of Systemic Janus Kinase Inhibitors for Vitiligo: An Evidence-Based Review
Authors: Siddhartha Sood, Ahmed Bagit, Jaymie Varenbut, Khalad Maliyar, Abrahim Abduelmula, Muskaan Sachdeva, Jorge Georgakopoulos, Asfandyar Mufti, Vimal Prajapati, Jensen Yeung
Journal: Journal of the American Academy of Dermatology (2024)